Key players in the Prurigo Nodularis situation:
Trevi Therapeutics、Galderma、Genentech、Incyte Corporation、Vyne Therapeutics Inc.、Celgene Corporation、Novartis、Pfizer、Regeneron Pharmaceuticals など。

Overview of the Prurigo Nodularis Treatment Market

(Albany, USA)– Title of DelveInsight’s latest report"Prurigo Nodularis Market Insights, Epidemiology, and Market Forecast - 2034."It offers a comprehensive assessment of the disease landscape across the 7MM (US, EU4 [Germany, France, Italy, Spain], UK, Japan) that offers detailed insights into historical and projected epidemiological trends, current treatment status, ongoing clinical trials, market dynamics, and forecast of Prurigo Nodularis market size for the study period 2020-2034.

The market study also encompasses analysis of treatment algorithms, penetration of emerging therapies, key market barriers and drivers, unmet medical needs and the evolving competitive landscape to provide a strategic roadmap for stakeholders.

? For a detailed outlook on growth, epidemiology, and drug uptake trends in the Prurigo Nodularis market, see below: Market forecast for prurigo nodularis

Key Insights from the Prurigo Nodularis Market Report

• The prurigo nodularis market has witnessed significant growth and is anticipated to register a promising CAGR throughout the forecast period (2020-2034).
  
  
• In March 2025,Insight (Nasdaq: INCY)Pivotal Phase 3 results from the TRuE-PN1 and TRuE-PN2 trials were presented, demonstrating safety and efficacy.Ruxolitinib cream 1.5% (Opzelura®)for adult PN patients. Data shared at the 2025 AAD Annual Meeting.
  
  
• In February 2025,GaldermaMarketing authorization has been granted by the UK MHRA and Swissmedic.Nemolizumab, suitable for moderate to severe prurigo nodularis and atopic dermatitis.
  
  
• In August 2024,Nemrubio® (nemolizumab)It has been approved by the US FDA as a prefilled subcutaneous formulation for adults with prurigo nodularis. The product previously achieved breakthrough and priority review status.
  
  
• In March 2024,InsightsPhase II findings announcedPovorcitinib, further enriching our pipeline.
  
  
• A 2022 study by Morgan et al. found that the estimated prevalence of PN was 3.27 per 10,000 people.
  
  
• The United States has the largest pool of patients diagnosed with PN in the 7MM.
  
  
• Now, DUPIXENT (dupilumab)remains the only FDA-approved treatment for PN and has a robust pipeline in development.
  
  

Understanding Prurigo Nodularis

Prurigo nodularis (PN) is a chronic inflammatory skin disease characterized by the appearance of multiple, intensely itchy nodules caused by prolonged scratching or skin trauma. The etiology remains unclear, but it is associated with comorbidities such as immune dysregulation, neurological abnormalities, atopic dermatitis, chronic kidney disease, HIV, and mental health disorders.

The disease severely impacts patients' quality of life due to relentless itching, causing sleep disorders, anxiety, depression and social stigma. Diagnosis is primarily clinical, but biopsy and laboratory tests may be required to rule out secondary conditions.

Treatment is centered on breaking the itch-scratch cycle with corticosteroids, calcineurin inhibitors, emollients, antihistamines, and, in advanced cases, systemic immunomodulators or biologics. Newer agents targeting the IL-31 and JAK pathways have shown promise in clinical trials.

? Download a free sample of the full report here: https://www.delveinsight.com/report-store/prurigo-nodularis-market

Epidemiology Overview

The epidemiological analysis in the report covers current and future trends across the 7MM from 2020 to 2034. It provides insights into:

• Total prevalence
  
  
• Severity-Based Segmentation
  
  
• Gender-specific trends
  
  
• Chronic and episodic diagnosis cases
  
  

? Let's take a closer look at these epidemiological changes: Epidemiological prediction of prurigo nodularis

Pipeline Development and Drug Uptake Trends

The drug uptake section focuses on market performance and patient adoption of both approved and pipeline drugs, assessing each drug's potential in terms of revenue, market share and usage.

Additionally, the report provides an overview of the therapeutics development landscape, providing insights into licensing, RD collaborations, clinical advancements, and pipeline transitions.

Key Pipeline Therapies:

• Nalbuphine IS– Trevi Therapeutics
  
  
• Nemolizumab– Galderma
  
  
• Bixarelimab (KPL-716)– Genentech
  
  
• Povorcitinib (INCB-54707)- Insight
  
  
• Ruxolitinib cream / INCB054707- Insight
  
  
• Serlopitant– Vine Therapeutics
  
  
• CC-10004– Celgene
  
  
• Pimecrolimus– Novartis
  
  
• Abrocitinib– Pfizer
  
  
• Dupilumab SAR231893– Regeneron
  
  

? Discover which treatments are expected to dominate the market share: Prurigo Nodularis Treatment Market

Market Dynamics: Drivers and Opportunities

Strengths:

• Innovative therapeutic mechanisms (e.g., IL-31 and JAK inhibitors) improve outcomes for patients facing debilitating symptoms.
  
  
• Emerging agents such as Vixarelimab show dual efficacy in reducing both itch and nodules.
  
  

opportunity:

• The increasing prevalence and underdiagnosis leave enormous scope for awareness campaigns and treatment innovation.
  
  
• With only one drug approved, there is a huge opportunity for players to introduce new treatments.
  
  

Report Scope

• Study period:2020-2034
  
  
• geography:US, EU5, UK, Japan
  
  
• Therapeutic focus:Commercial and Pipeline Therapeutics
  
  
• analyze:Market dynamics, SWOT, PESTLE, Porter's five forces, market entry strategies, reimbursement, KOL insights
  
  

? To find out about treatment evaluations and clinical activities, please visit: Clinical trials and treatment evaluations for prurigo nodularis

Table of Contents (TOC) Snapshot

1. introduction
   
   
2. executive summary
   
   
3. SWOT Analysis
   
   
4. Patient share analysis
   
   
5. Market Overview
   
   
6. Background of the disease
   
   
7. Epidemiology
   
   
8. Country-level insights
   
   
9. Current medical practice
   
   
10. Unmet needs
    
    
11. New Treatments
    
    
12. Market forecasts (2020-2034)
    
    
13. Market Analysis by Country
    
    
14. Market Access and Reimbursement
    
    
15. Market Drivers
    
    
16. Market Barriers
    17-21. Appendix, Methodology, and DelveInsight
    
    

About DelveInsight

DelveInsight is a leading healthcare market research and business consulting firm specializing in life sciences. The company provides deep, actionable insights and end-to-end solutions customized to support strategic, clinical and commercial decision-making for pharmaceutical and biotechnology companies.